Methyl 3-amino-2,4-dichloro-5-fluorobenzoate, 95+%, 50mg

ETHYL 8-BROMOIMIDAZO[1,2-A]PYRIDINE-2-CARBOXYLATE, 95.0%, 1g

Polytungstate de sodium hydraté, min 99,9 %, pa, 250 g, emballage plastique.

Oxion Inverso OX.2003-PLPH avec objectifs LWD Plan phase 10x/20x/40x

1-[3,5-bis(trifluoromethyl)phenyl]-3-[(S)-[(1S,2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl](6-methoxyquinolin-4-yl)methyl]thiourea, 97, 5g

1-Ethyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)thiourea, 97%, 1g

4-Bromobenzyl methyl sulfide, 97.0%, 2g

n-[3-(benzyloxy)pyridin-2-yl]benzenesulfonamide, 98%, 250mg

Ethyl 5-methyl-4-oxo-1,4-dihydropyrrolo[2,1-f][1,2,4]triazine-6-carboxylate, 95.0%, 1g

3-Bromopyrrolidin-2-one, 95.0%, 250mg

L-tert-Leucine, 98.0%, 1g

N-(2-Cyanoethyl)glycine, 95.0%, 25g

Gel de silice Jaune/Bleu, 2,5-6 mm, avec indicateur, cassé, 2,5 kg, emballage plastique.